Loading...

LYEL LYELL IMMUNOPHARMA INC Capital Structure Changes 8-K Filing

LYLL

LYL

LYELL IMMUNOPHARMA INC

(LYEL)

2025 8-K

Clinical Data Update

Bylaw Amendments

Financial Results Release

Exclusive License Agreement

Management Changes

Management Change

Equity Offerings

Merger of Equals

New Clinical Data

Financial Statements

Facility Closure

Financial Results

Acquisition Completed

Clinical Data Release

Board Resignation

Financial Results

Merger Completion

Merger Agreement

Earnings Report

Phase 1 Trial Data Announce...

Earnings Report

Earnings Reports

Repricing of Underwater Opt...

Financial Results Announcement

Investor Presentation

Earnings Report

Annual Meeting of Stockholders

Resignation of Chief Legal ...

Earnings Report

Earnings Reports

External Links:

On July 24, 2025, Lyell Immunopharma, Inc. entered into a Securities Purchase Agreement to sell 3,753,752 shares of common stock at $13.32 each, raising approximately $50 million, with potential additional sales based on clinical milestones.

AI Assistant

LYELL IMMUNOPHARMA INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.